APGE - CIK 0001974640
The table below shows Apogee Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $60.82M | $54.18M | $55.70M | $46.39M | $45.71M | $33.21M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $21.95M |
| $17.10M |
| $17.46M |
| $16.71M |
| $12.97M |
| $10.92M |
| Operating income | -$82.77M | -$71.28M | -$73.17M | -$63.10M | -$58.69M | -$44.12M |
| Income tax | $79.00K | $61.00K | $72.00K | $83.00K | $0.00 | $0.00 |
| Net income | -$74.11M | -$65.02M | -$66.10M | -$55.34M | -$49.02M | -$33.82M |
| EPS (diluted) | -$1.06 | -$1.11 | -$1.13 | -$0.95 | -$0.86 | -$0.60 |